Biotech Values

[oc631]

Does this imply that 12 weeks of treatment will not be sufficient? Did GILD have some later relapsers previously?

GILD claims to have achieved higher SVR rates in GT3 patients by dosing Sofo/Riba for 16-weeks, as opposed to 12. This study is exploring 16 and 24-week durations.

The surprise here is the addition of GT1 patients using longer durations of Sofo/Riba without their NS5A (GS-5885).


GILD needs a better NS5A in GT3, not longer durations of dosing. This study will read out long after a decision is made on Sofo/Riba in GT2/GT3. You could say this is window dressing in support of the NDA within these genotypes.